Milestones
SYMLIN™ – Report titration study data
AC2993 – Initial Phase 3 results
AC2993 LAR – Start additional Phase 2 studies
AC2993 – Complete Phase 3
AC162352 (PYY [3-36]) – Submit IND
SYMLIN™ – FDA decision expected
SYMLIN™ – Launch, subject to FDA approval